DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Leerink Swann increased their FY2018 earnings per share (EPS) estimates for DexCom in a note issued to investors on Tuesday, November 6th. Leerink Swann analyst D. Antalffy now forecasts that the medical device company will post earnings of ($0.16) per share for the year, up from their prior forecast of ($0.54). Leerink Swann also issued estimates for DexCom’s Q4 2018 earnings at $0.07 EPS, Q1 2019 earnings at $0.06 EPS, Q2 2019 earnings at $0.08 EPS, Q3 2019 earnings at $0.10 EPS, Q4 2019 earnings at $0.12 EPS, FY2019 earnings at $0.35 EPS, FY2020 earnings at $0.89 EPS, FY2021 earnings at $1.51 EPS and FY2022 earnings at $2.20 EPS.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.29. DexCom had a net margin of 4.72% and a negative return on equity of 3.08%. The firm had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. The firm’s revenue for the quarter was up 44.5% on a year-over-year basis.
A number of other brokerages have also recently weighed in on DXCM. Northland Securities raised shares of DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Raymond James boosted their price target on shares of DexCom from $125.00 to $150.00 and gave the company an “outperform” rating in a research report on Tuesday, October 23rd. BidaskClub raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 21st. Oppenheimer set a $150.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Wednesday. Finally, Piper Jaffray Companies upped their target price on shares of DexCom to $157.00 and gave the company an “overweight” rating in a report on Wednesday. Eight analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $132.50.
Shares of DXCM opened at $148.41 on Friday. DexCom has a 1-year low of $49.17 and a 1-year high of $152.14. The firm has a market capitalization of $11.74 billion, a P/E ratio of -255.88 and a beta of 0.60. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62.
A number of hedge funds and other institutional investors have recently bought and sold shares of DXCM. Stratos Wealth Partners LTD. acquired a new position in DexCom during the third quarter worth about $124,000. IBM Retirement Fund acquired a new stake in shares of DexCom in the third quarter valued at approximately $203,000. Brighton Jones LLC acquired a new stake in shares of DexCom in the third quarter valued at approximately $204,000. Strs Ohio acquired a new stake in shares of DexCom in the third quarter valued at approximately $213,000. Finally, 1ST Source Bank acquired a new stake in shares of DexCom in the third quarter valued at approximately $230,000.
In related news, EVP Steven Robert Pacelli sold 3,114 shares of the stock in a transaction dated Tuesday, October 23rd. The shares were sold at an average price of $128.85, for a total transaction of $401,238.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 11,161 shares of the stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $123.22, for a total transaction of $1,375,258.42. The disclosure for this sale can be found here. Insiders have sold 157,892 shares of company stock valued at $21,864,030 over the last three months. 1.80% of the stock is currently owned by corporate insiders.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.